| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
1 Apoptosis Department, Institute for Cancer Biology, Danish Cancer Society, Copenhagen, Denmark; 2 Institute of Human Genetics, University of Würzburg, Würzburg, Germany; 3 Department of Pathology, Harvard Medical School, Boston, Massachusetts; 4 Institute of Physiological Chemistry, Medical Faculty, Martin-Luther-University Halle-Wittenberg, Halle, Germany; and 5 Disease Biology, H. Lundbeck A/S, Valby, Denmark
Tumorigenesis is associated with several changes that alter the cellular susceptibility to programmed cell death. Here, we show that immortalization and transformation sensitize cells in particular to the cysteine cathepsin-mediated lysosomal death pathway. Spontaneous immortalization increased the susceptibility of wild-type murine embryonic fibroblasts (MEFs) to tumor necrosis factor (TNF)-mediated cytotoxicity >1000-fold, whereas immortalized MEFs deficient for lysosomal cysteine protease cathepsin B (CathB) retained the resistant phenotype of primary cells. This effect was specific for cysteine cathepsins, because also lack of cathepsin L (a lysosomal cysteine protease), but not that of cathepsin D (a lysosomal aspartyl protease) or caspase-3 (the major executioner protease in classic apoptosis) inhibited the immortalization-associated sensitization of MEFs to TNF. Oncogene-driven transformation of immortalized MEFs was associated with a dramatic increase in cathepsin expression and additional sensitization to the cysteine cathepsin-mediated death pathway. Importantly, exogenous expression of CathB partially reversed the resistant phenotype of immortalized CathB-deficient MEFs, and the inhibition of CathB activity by pharmacological inhibitors or RNA interference attenuated TNF-induced cytotoxicity in immortalized and transformed wild-type cells. Thus, tumorigenesis-associated changes in lysosomes may counteract cancer progression and enhance therapeutic responses by sensitizing cells to programmed cell death.
This article has been cited by other articles:
![]() |
G. Zhang, M. A. Park, C. Mitchell, H. Hamed, M. Rahmani, A. P. Martin, D. T. Curiel, A. Yacoub, M. Graf, R. Lee, et al. Vorinostat and Sorafenib Synergistically Kill Tumor Cells via FLIP Suppression and CD95 Activation Clin. Cancer Res., September 1, 2008; 14(17): 5385 - 5399. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Fehrenbacher, L. Bastholm, T. Kirkegaard-Sorensen, B. Rafn, T. Bottzauw, C. Nielsen, E. Weber, S. Shirasawa, T. Kallunki, and M. Jaattela Sensitization to the Lysosomal Cell Death Pathway by Oncogene-Induced Down-regulation of Lysosome-Associated Membrane Proteins 1 and 2 Cancer Res., August 15, 2008; 68(16): 6623 - 6633. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Park, A. Yacoub, M. Rahmani, G. Zhang, L. Hart, M. P. Hagan, S. K. Calderwood, M. Y. Sherman, C. Koumenis, S. Spiegel, et al. OSU-03012 Stimulates PKR-Like Endoplasmic Reticulum-Dependent Increases in 70-kDa Heat Shock Protein Expression, Attenuating Its Lethal Actions in Transformed Cells Mol. Pharmacol., April 1, 2008; 73(4): 1168 - 1184. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. D. Johansen, T. Naumanen, A. Knudsen, N. Westerlund, I. Gromova, M. Junttila, C. Nielsen, T. Bottzauw, A. Tolkovsky, J. Westermarck, et al. IKAP localizes to membrane ruffles with filamin A and regulates actin cytoskeleton organization and cell migration J. Cell Sci., March 15, 2008; 121(6): 854 - 864. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. W. Werneburg, M. E. Guicciardi, S. F. Bronk, S. H. Kaufmann, and G. J. Gores Tumor Necrosis Factor-related Apoptosis-inducing Ligand Activates a Lysosomal Pathway of Apoptosis That Is Regulated by Bcl-2 Proteins J. Biol. Chem., September 28, 2007; 282(39): 28960 - 28970. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Guicciardi, S. F. Bronk, N. W. Werneburg, and G. J. Gores cFLIPL prevents TRAIL-induced apoptosis of hepatocellular carcinoma cells by inhibiting the lysosomal pathway of apoptosis Am J Physiol Gastrointest Liver Physiol, May 1, 2007; 292(5): G1337 - G1346. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Daugaard, T. Kirkegaard-Sorensen, M. S. Ostenfeld, M. Aaboe, M. Hoyer-Hansen, T. F. Orntoft, M. Rohde, and M. Jaattela Lens Epithelium-Derived Growth Factor Is an Hsp70-2 Regulated Guardian of Lysosomal Stability in Human Cancer Cancer Res., March 15, 2007; 67(6): 2559 - 2567. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Groth-Pedersen, M. S. Ostenfeld, M. Hoyer-Hansen, J. Nylandsted, and M. Jaattela Vincristine Induces Dramatic Lysosomal Changes and Sensitizes Cancer Cells to Lysosome-Destabilizing Siramesine Cancer Res., March 1, 2007; 67(5): 2217 - 2225. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kitareewan, B. D. Roebuck, E. Demidenko, R. D. Sloboda, and E. Dmitrovsky Lysosomes and Trivalent Arsenic Treatment in Acute Promyelocytic Leukemia J Natl Cancer Inst, January 3, 2007; 99(1): 41 - 52. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gyrd-Hansen, T. Farkas, N. Fehrenbacher, L. Bastholm, M. Hoyer-Hansen, F. Elling, D. Wallach, R. Flavell, G. Kroemer, J. Nylandsted, et al. Apoptosome-Independent Activation of the Lysosomal Cell Death Pathway by Caspase-9 Mol. Cell. Biol., November 1, 2006; 26(21): 7880 - 7891. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. D. Petty, K. M. Kerr, G. I. Murray, M. C. Nicolson, P. H. Rooney, D. Bissett, and E. S.R. Collie-Duguid Tumor Transcriptome Reveals the Predictive and Prognostic Impact of Lysosomal Protease Inhibitors in Non-Small-Cell Lung Cancer J. Clin. Oncol., April 10, 2006; 24(11): 1729 - 1744. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Ostenfeld, N. Fehrenbacher, M. Hoyer-Hansen, C. Thomsen, T. Farkas, and M. Jaattela Effective Tumor Cell Death by {sigma}-2 Receptor Ligand Siramesine Involves Lysosomal Leakage and Oxidative Stress Cancer Res., October 1, 2005; 65(19): 8975 - 8983. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Fehrenbacher and M. Jaattela Lysosomes as Targets for Cancer Therapy Cancer Res., April 15, 2005; 65(8): 2993 - 2995. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Thorburn, F. Moore, A. Rao, W. W. Barclay, L. R. Thomas, K. W. Grant, S. D. Cramer, and A. Thorburn Selective Inactivation of a Fas-associated Death Domain Protein (FADD)-dependent Apoptosis and Autophagy Pathway in Immortal Epithelial Cells Mol. Biol. Cell, March 1, 2005; 16(3): 1189 - 1199. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Erdal, M. Berndtsson, J. Castro, U. Brunk, M. C. Shoshan, and S. Linder Induction of lysosomal membrane permeabilization by compounds that activate p53-independent apoptosis PNAS, January 4, 2005; 102(1): 192 - 197. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. Syljuasen, C. S. Sorensen, J. Nylandsted, C. Lukas, J. Lukas, and J. Bartek Inhibition of Chk1 by CEP-3891 Accelerates Mitotic Nuclear Fragmentation in Response to Ionizing Radiation Cancer Res., December 15, 2004; 64(24): 9035 - 9040. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |